A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 48,082 shares of FATE stock, worth $157,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,082
Holding current value
$157,708
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.54 - $8.35 $170,210 - $401,484
48,082 New
48,082 $352,000
Q3 2023

Nov 15, 2023

SELL
$2.02 - $5.04 $8,936 - $22,296
-4,424 Reduced 8.1%
50,187 $106,000
Q2 2023

Aug 14, 2023

BUY
$4.76 - $6.59 $10,362 - $14,346
2,177 Added 4.15%
54,611 $259,000
Q1 2023

May 15, 2023

SELL
$4.24 - $11.12 $1,484 - $3,891
-350 Reduced 0.66%
52,434 $299,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $57,040 - $137,856
5,785 Added 12.31%
52,784 $533,000
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $216,375 - $370,841
10,284 Added 28.01%
46,999 $1.05 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $384,065 - $915,666
21,601 Added 142.92%
36,715 $910,000
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $545,957 - $1.11 Million
-18,401 Reduced 54.9%
15,114 $586,000
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $1.6 Million - $2.16 Million
33,515 New
33,515 $1.96 Million
Q2 2021

Aug 16, 2021

SELL
$67.25 - $92.52 $239,410 - $329,371
-3,560 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$72.16 - $117.4 $256,889 - $417,944
3,560 New
3,560 $294,000
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $1.6 Million - $4.24 Million
-42,035 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $131,523 - $175,162
4,325 Added 11.47%
42,035 $1.68 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $762,119 - $1.33 Million
37,710 New
37,710 $1.29 Million
Q4 2019

Feb 14, 2020

SELL
$13.39 - $20.73 $622,420 - $963,613
-46,484 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$15.47 - $22.5 $719,107 - $1.05 Million
46,484 New
46,484 $722,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $318M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.